In today’s briefing:
- SCLX: Revenues Beat Estimates in 2Q
SCLX: Revenues Beat Estimates in 2Q
- SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.
- The company already has commercialized products that are proven to improve patients’ lives.
- The company released its 2Q2024 results that showed revenues that bested estimates as sales of its primary products showed robust growth, while adding another product to its mix.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
